230 related articles for article (PubMed ID: 37166496)
1. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.
Kong Y; Xie F; Zhang Z; Wang S; Zhang Y; Di Y; Zhou Z; Jiang D; Li J; Huang Q; Wang J; Li X; Pan Z; Ni R; Guan Y
Eur Radiol; 2023 Oct; 33(10):7077-7088. PubMed ID: 37166496
[TBL] [Abstract][Full Text] [Related]
2.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
3. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with
Watabe T; Kabayama K; Naka S; Yamamoto R; Kaneda K; Serada S; Ooe K; Toyoshima A; Wang Y; Haba H; Kurimoto K; Kobayashi T; Shimosegawa E; Tomiyama N; Fukase K; Naka T
J Nucl Med; 2023 Dec; 64(12):1949-1955. PubMed ID: 37827841
[TBL] [Abstract][Full Text] [Related]
4. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma.
Li M; Wei W; Barnhart TE; Jiang D; Cao T; Fan K; Engle JW; Liu J; Chen W; Cai W
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2737-2748. PubMed ID: 33537836
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of
Prignon A; Provost C; Alshoukr F; Wendum D; Couvelard A; Barbet J; Forgez P; Talbot JN; Gruaz-Guyon A
Mol Pharm; 2019 Jun; 16(6):2776-2784. PubMed ID: 31013092
[TBL] [Abstract][Full Text] [Related]
7. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
[No Abstract] [Full Text] [Related]
8. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting of CEACAM6 using antibody probes of different sizes.
Niu G; Murad YM; Gao H; Hu S; Guo N; Jacobson O; Nguyen TD; Zhang J; Chen X
J Control Release; 2012 Jul; 161(1):18-24. PubMed ID: 22568933
[TBL] [Abstract][Full Text] [Related]
10. ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers.
Liang C; Huang W; Zhang Y; Zhang D; An S; Wu Q; Zhao H; Wang C; Huang G; Wei W; Liu J
Mol Pharm; 2023 Aug; 20(8):4184-4195. PubMed ID: 37403817
[TBL] [Abstract][Full Text] [Related]
11. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
12. A Novel Approach for Image-Guided
Schug C; Gupta A; Urnauer S; Steiger K; Cheung PF; Neander C; Savvatakis K; Schmohl KA; Trajkovic-Arsic M; Schwenk N; Schwaiger M; Nelson PJ; Siveke JT; Spitzweg C
Mol Cancer Res; 2019 Jan; 17(1):310-320. PubMed ID: 30224540
[TBL] [Abstract][Full Text] [Related]
13. Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28.
Lanfranca MP; Lazarus J; Shao X; Nathan H; Di Magliano MP; Zou W; Piert M; Frankel TL
J Surg Res; 2018 Dec; 232():570-577. PubMed ID: 30463776
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma.
Strickland LA; Ross J; Williams S; Ross S; Romero M; Spencer S; Erickson R; Sutcliffe J; Verbeke C; Polakis P; van Bruggen N; Koeppen H
J Pathol; 2009 Jul; 218(3):380-90. PubMed ID: 19334050
[TBL] [Abstract][Full Text] [Related]
15. Development of [
Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
[TBL] [Abstract][Full Text] [Related]
16. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
Kryza T; Khan T; Puttick S; Li C; Sokolowski KA; Tse BW; Cuda T; Lyons N; Gough M; Yin J; Parkin A; Deryugina EI; Quigley JP; Law RHP; Whisstock JC; Riddell AD; Barbour AP; Wyld DK; Thomas PA; Rose S; Snell CE; Pajic M; He Y; Hooper JD
Theranostics; 2020; 10(9):4116-4133. PubMed ID: 32226543
[No Abstract] [Full Text] [Related]
17. An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer.
Wang Q; Wang J; Yan H; Li Z; Wang K; Kang F; Tian J; Zhao X; Yun SH
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1765-1779. PubMed ID: 36692541
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.
Yin X; Wang M; Wang H; Deng H; He T; Tan Y; Zhu Z; Wu Z; Hu S; Li Z
Amino Acids; 2017 Aug; 49(8):1325-1335. PubMed ID: 28536844
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Montemagno C; Cassim S; De Leiris N; Durivault J; Faraggi M; Pagès G
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
